Sivick, Kelsey E.

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

Corrales, L., Glickman, L. H., McWhirter, S. M., Kanne, D. B., Sivick, K. E., Katibah, G. E., Woo, S.-R., Lemmens, E., Banda, T., Leong, J. J., et al. (2015) · Cell Reports

interferon and immune responsesImmunotherapy and Immune Responses

Cited by 1,560

STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade

Fu, J., Kanne, D. B., Leong, M., Glickman, L. H., McWhirter, S. M., Lemmens, E., Mechette, K., Leong, J. J., Lauer, P., Liu, W., et al. (2015) · Science Translational Medicine

Immunotherapy and Immune Responsesinterferon and immune responses

Cited by 720

Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity

Sivick, K. E., Desbien, A. L., Glickman, L. H., Reiner, G. L., Corrales, L., Surh, N. H., Hudson, T. E., Vu, U. T., Francica, B. J., Banda, T., et al. (2018) · Cell Reports

Cancer Immunotherapy and Biomarkersinterferon and immune responses

Cited by 451

Mucosal Immunization with Iron Receptor Antigens Protects against Urinary Tract Infection

Alteri, C. J., Hagan, E. C., Sivick, K. E., Smith, S. N., & Mobley, H. L. T. (2009) · PLoS Pathogens

Escherichia coli research studiesUrinary Tract Infections Management

Cited by 201

Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity

Sivick, K. E., Desbien, A. L., Glickman, L. H., Reiner, G. L., Corrales, L., Surh, N. H., Hudson, T. E., Vu, U. T., Francica, B. J., Banda, T., et al. (2019) · Cell Reports

interferon and immune responsesImmunotherapy and Immune Responses

Cited by 53